

Peng Song

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5418690/peng-song-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

125
citations

7
h-index

10
g-index

23
ext. papers

182
ext. citations

2.9
avg, IF

3.26
L-index

#	Paper	IF	Citations
17	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021 , 10, 188-198	4.8	6
16	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1216-1223	3.2	4
15	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 2406-2430	3.2	14
14	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020 , 11, 498-504	3.2	6
13	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 1647-1654	3.2	9
12	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , 2020 , 11, 1621-1632	3.2	18
11	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. <i>Cancer Management and Research</i> , 2020 , 12, 5975-5985	3.6	3
10	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 2077-2086	3.2	0
9	Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2019 , 12, 8151-8159	4.4	7
8	Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. <i>European Journal of Cancer</i> , 2019 , 121, 4-6	7.5	7
7	Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer. <i>OncoTargets and Therapy</i> , 2019 , 12, 2943-2948	4.4	2
6	Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019 , 11, 258-265	3.5	10
5	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. <i>Thoracic Cancer</i> , 2019 , 10, 1303-1309	3.2	6
4	Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. <i>Scientific Reports</i> , 2019 , 9, 4278	4.9	19
3	Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). <i>Thoracic Cancer</i> , 2019 , 10, 587-592	3.2	8
2	Refractory chylous pleural effusion with systemic lupus erythematosus : Surgical treatment when steroid/immunosuppressant resistant. <i>Zeitschrift Fur Rheumatologie</i> , 2019 , 78, 797-802	1.9	2
1	Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant. <i>Thoracic Cancer</i> , 2018 , 9, 1327-1332	3.2	1

